Repurposing SGLT2 and DPP‐4 inhibitors for mild cognitive impairment in type 2 diabetes mellitus: Insights from proteomics, target prediction and molecular docking
These findings are significant in tailoring T2D treatment to reduce cognitive complications and exploring drug design to target neuroinflammatory disorders.
Authors
- Noha Alaa Hamdy (ORCID: https://orcid.org/0000-0002-4606-8567)
- Yehia Mechref
- Mahmoud Agami
- Md Abdul Hakim (ORCID: https://orcid.org/0000-0002-6183-7950)
- Perihan A. Elzahhar
- Labiba K. El‐Khordagui
- Marina Naldi
- Ahmed F. El‐Yazbi
- Akeem Sanni
- Nayera W. Hassan
- Rosaria Spagnuolo (ORCID: https://orcid.org/0009-0002-0289-6763)
- Sherifdeen Onigbinde (ORCID: https://orcid.org/0000-0001-6791-7989)
- Vishal Sandilya
- Waziha Purba
- Shams T Osman
- Md Mostofa Al Amin Bhuiyan
- Manuela Bartolini
- Ahmed S. F. Belal
Institutions
- Texas Tech University (US)
- AlAlamein International University (EG)
- Alexandria University (EG)
- University of Bologna (IT)
Publication Details
- Journal
- British Journal of Pharmacology
- Published
- 2026-01-26
- DOI
- https://doi.org/10.1111/bph.70331
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00